Last $0.27 USD
Change Today -0.0004 / -0.15%
Volume 267.0K
HEB On Other Exchanges
As of 12:50 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

hemispherx biopharma inc (HEB) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/23/14 - $0.55
52 Week Low
11/25/13 - $0.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

hemispherx biopharma inc (HEB) Related Bloomberg News

View More Bloomberg News

hemispherx biopharma inc (HEB) Related Businessweek News

No Related Businessweek News Found

hemispherx biopharma inc (HEB) Details

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company products comprise Ampligen, an experimental drug, which is under clinical development for the treatment of chronic fatigue syndrome, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma. Its products also include Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza, seasonal influenza, and other emerging viruses. The company has a strategic alliance with Bioclones (Pty) Ltd. to develop various projects. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

39 Employees
Last Reported Date: 03/14/14
Founded in 1990

hemispherx biopharma inc (HEB) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.0M
Executive Vice Chairman, Chief Financial Offi...
Total Annual Compensation: $553.8K
Chief Medical Officer and Medical Director
Total Annual Compensation: $265.5K
Compensation as of Fiscal Year 2013.

hemispherx biopharma inc (HEB) Key Developments

Hemispherx Biopharma Announces Earnings Results for the Third Quarter Nine Months Ended September 30, 2014

Hemispherx Biopharma announced earnings results for the third quarter nine months ended September 30, 2014. For the quarter, the company reported net loss (including non-cash effects) of approximately $4,202,000 or $0.02 per share against $5,136,000 or $0.03 per share a year ago. Total revenues were $45,000, compared to $36,000 for the same quarter ended September 30, 2013. For the nine months, the company reported net loss (including non-cash effects) of approximately $12,994,000 or $0.07 per share against $13,030,000 or $0.08 per share a year ago. Total revenues were $157,000, compared to $114,000 for the same period ended September 30, 2013.

Hemispherx Biopharma and Sage Group Prevails in Multi-Million Dollar Federal Lawsuit

Hemispherx Biopharma, Inc. announced that a federal judge in Delaware has dismissed all claims against Hemispherx and the Sage Group brought by Cato Capital in an order and decision dated September 29, 2014. The decision comes following a three day trial before a judge in the United States District Court for the District of Delaware, which considered several multimillion dollar claims brought by Cato Capital. The Court's order completely vindicated Hemispherx and the Sage Group of any wrongdoing and denied Cato Capital's claims against Hemispherx for breach of contract and fraudulent inducement. On October 14, 2014, Hemispherx' lead trial counsel James J. Black, filed a motion for recovery of fees and costs seeking recovery for Hemispherx of approximately one million dollars based upon contractual fee shifting provisions in the subject contract.

Hemispherx Biopharma, Inc., Annual General Meeting, Nov 12, 2014

Hemispherx Biopharma, Inc., Annual General Meeting, Nov 12, 2014., at 10:00 US Eastern Standard Time. Location: Embassy Suites Hotel. Agenda: To elect five members to the Board of Directors to serve until their respective successors are elected and qualified; to ratify the selection by Audit Committee of McGladrey LLP, independent registered public accountants, to audit the financial statements for the year ending December 31, 2014; to approve, by non-binding vote, executive compensation; and to transact such other matters as may properly come before the meeting or any adjournment thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEB:US $0.27 USD -0.0004

HEB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $259.25 USD +0.76
AstraZeneca PLC 4,741 GBp +30.00
Baxter International Inc $72.61 USD +0.62
Medigene AG €3.78 EUR +0.075
Sarepta Therapeutics Inc $15.89 USD +0.11
View Industry Companies

Industry Analysis


Industry Average

Valuation HEB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 258.7x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 181.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMISPHERX BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at